Page 2 - Ioscience News Today

Following its $10 million Series A financing  in July 2023, Camena Bioscience has appointed Dr Nicola Thompson as Chair of its Board of Directors as part of plans for commercial expansion of its DNA synthesis platform, gSynth™. Click to read more...

In New York, we are one step away from ensuring access to biomarker testing for millions of residents who stand to benefit. The final step is for Governor Hochul to

SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that H.E Dr. Jean Kaseya, Director General of Africa CDC visited SK bioscience headquarters on November 3 to discuss collaboration with the Partnerships for African Vaccine Manufacturing (PAVM).

The University of Georgia has introduced a Ph.D. program in regenerative bioscience. The formalized doctoral program, set to launch in spring 2024 is the first to be offered in the

Vancouver, Canada, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Renaissance BioScience Corp (www.renaissancebioscience.com), a leader in bioengineering for the global agriculture, animal health, human medicine, and food sector, is pleased to announce its recent patent award from the China patent office. This patent grant, representing the first for its innovative yeast-based platform technology for the production and delivery of RNA bioactive molecules, enhances Renaissance's robust IP portfolio, whic...

Hyundai Bioscience announced that Xafty™, a broad-spectrum antiviral drug, can solve RNA virus infections, capable of treating both COVID-19 and Dengue fever or Dengue virus infection". It was announced on October 13, 2023, at IDWeek 2023, a prestigious conference in the field of infectious diseases held in Boston.

Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The

Ground-breaking research by Tamryn Marsberg and Michael Jukes has led to the development of two viral-based biopesticides.

Content by MilliporeSigma. Locally, at MilliporeSigma, science starts with Bob DeMoulin and his mini but mighty team of 40 colleagues working out of the Barton Distribution Center in St. Louis,

$Vaxxas, a clinical-stage biotech firm pioneering a needle-free vaccine patch, announced a AU$5. Click to read more...